Dr Franz Humer is Chairman of Neogene Therapeutics, HMNC Brain Health, Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. He is a Board Director of Allogene Therapeutics, Cydar and Emil Frey Holdings and an Advisor to Temasek Holdings, Letterone Healthcare, Target PharmaSolutions and Breakthrough Properties in addition to a number of start-up companies.
Professional experience from positions in the pharmaceuticals industry at, among others, Schering Plough Corp. and Glaxo where he was Managing Director of Glaxo Pharmaceuticals UK and a member of the Board of Glaxo Holdings plc. In 1995, he joined Hoffmann-La Roche as a member of its Board and the head of its Pharmaceutical Division, progressing to become Chairman and CEO in 2001, and between 2008 and 2014 the Chairman of Roche Holding Limited.
Franz was also Chairman of Diageo, the world’s leading spirits company, and an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd (Japan), Arix Bioscience plc and Kite Pharma (biotech company in Los Angeles).